Carlos Campos, a family physician based in south-central Texas, has emerged as a significant figure in promoting GLP-1 drugs, a class of medications used primarily for weight loss and diabetes management. While Campos continues to treat patients for a variety of health conditions, his role extends beyond clinical care into what he describes as a form of medical advocacy, funded by pharmaceutical companies.

Over the past seven years, Campos has received nearly $1 million from drug manufacturers to educate other healthcare professionals about GLP-1 medications. His work involves speaking engagements and educational sessions aimed at encouraging doctors to prescribe these drugs. Campos likens his role to that of an “evangelical preacher,” emphasizing the science and benefits behind the medication to his peers.

These promotional activities take place in a variety of settings, ranging from private dining rooms at upscale restaurants to more casual environments such as primary care offices. Through these efforts, drug companies seek to increase awareness and acceptance of GLP-1 drugs among medical providers, ultimately aiming to expand the market for these treatments.

GLP-1 medications have gained significant attention in recent years due to their effectiveness in helping patients achieve weight loss as well as better manage blood sugar levels. The rise in demand has been accompanied by an increase in pharmaceutical marketing geared toward prescribers, highlighting the growing commercial importance of this drug class.

While proponents highlight the therapeutic benefits of GLP-1 drugs, critics caution about the influence of industry-funded promotion on prescribing habits. The involvement of physicians like Campos underscores the complex relationship between healthcare providers and pharmaceutical companies in the expanding landscape of weight-loss and diabetes medications.

Campos’s dual role as a clinician and paid advocate exemplifies the multifaceted dynamics driving the current weight-loss drug trend, illustrating how pharmaceutical companies engage trusted medical professionals to support their sales strategies.